top of page

Immunoncology Lab

Lab Director

Alvaro Lladser

T cells have the potential to eliminate cancer cells. Immunotherapies that exploit this ability have become a standard of care across different cancers. Emerging evidence indicates that effective and long-lasting antitumor protection is determined by the interplay of circulating and tissue-resident T cells with other immune cells in the tumor microenvironment and lymph nodes. We are comprehensively studying the molecular and cellular networks interplay of circulating and tissue-resident T cell compartments in human cancers using functional assays, multidimensional flow cytometry, single-cell and spatial transcriptomics, and in vivo models. We aim to reveal new insights into these networks that impact cancer progression and harness this knowledge to improve immunotherapies.

Lab Members

Research Associates

Vincenzo Borgna, MD, PhD

Andrés Hernández-Oliveras, PhD


Postdoctoral fellow

Sofía Hidalgo, PhD

Latest Publications

Nature Communications

March 31, 2026

Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models

Oncoimmunology

February 24, 2026

Contrasting functions of CD73 and adenosine in CD8+ T-cell exhaustion during antitumor immunity

Oncoimmunology

December 31, 2025

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models

Latest Publications

Nature Communications

March 31, 2026

Oncoimmunology

February 24, 2026

Oncoimmunology

December 31, 2025
bottom of page